drugset
drugset / Trial / NCT00706069

Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer

NCT00706069 ↗

Phase 1 Completed 40 enrolled Hellenic Oncology Research Group University Hospital of Crete · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the toxicity and secondary the efficacy of the combination vinorelbine plus capecitabine in metastatic breast cancer patients

Timeline

Start
2008-06
Primary completion
2009-07
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 800 mg/m2 Oral
Subject Capecitabine Small molecule 950 mg/m2 Oral
Subject Capecitabine Small molecule 1100 mg/m2 Oral
Subject Capecitabine Small molecule 1250 mg/m2 Oral
Subject Vinorelbine Small molecule 30 mg Oral
Subject Vinorelbine Small molecule 40 mg Oral
Subject Vinorelbine Small molecule 50 mg Oral
Subject Vinorelbine Small molecule 60 mg Oral

Indications

breast cancer